Crisaborole Unlocked: The Definitive Resource for API Sourcing, Manufacturing & Compounding Excellence

Get A Quick Quote for Crisaborole API

The global atopic dermatitis market is projected to reach $24.6 billion by 2030, with non-steroidal PDE4 inhibitors, such as Crisaborole, driving 18% CAGR growth.

For crisaborole API importers, generic manufacturers, and compounding pharmacies, mastering the sourcing and formulation of Crisaborole is crucial to capturing this rapidly growing market.

This definitive guide delivers actionable intelligence – from molecular insights to bulk procurement tactics – positioning your organization at the forefront of dermatological innovation.

What is Crisaborole?

Crisaborole is a boron-containing small molecule (C14H10BNO3, MW 251.06 g/mol) classified as a phosphodiesterase-4 (PDE4) inhibitor.

First approved by the FDA in 2016, it represents a breakthrough in non-steroidal topical therapy.

Key Pharmaceutical Characteristics:

Chemical Name: 5-((4-Cyanophenoxy)methyl)-2,1,3-benzoxaborol-1(3H)-ol
CAS Registry: 906673-24-3
Appearance: White to off-white crystalline powder
Solubility: Sparingly soluble in water (<0.1 mg/mL), soluble in DMSO (>50 mg/mL)
Melting Point: 198-202°C (with decomposition)

Regulatory Status Highlights:

FDA Approved: December 2016 (NDA 207695)
EMA Approved: October 2020 (EU/1/20/1490)
WHO INN: Crisaborolum

Is Crisaborole a Steroid?

No – and this is its core competitive advantage.

Crisaborole belongs to the benzoxaborole class, distinct from corticosteroids both structurally and mechanistically. This steroid-free profile directly addresses critical market needs:

Why Steroid-Free Matters to Your Business:

Market Differentiation: Position against generic steroid creams (e.g., hydrocortisone)
Safety-Driven Formulations: Eliminate corticosteroid side effects (skin atrophy, tachyphylaxis)
Pediatric Focus: Preferred for children >3 months (steroids restricted in young demographics)
Compounding Synergy: Combine with emollients without steroid stability concerns

What Are the Brand Names of Crisaborole?

Brand Name	Marketer	Strength	Market Coverage
Eucrisa®	Pfizer	2% Ointment	USA, Canada, EU
Stelocrom™	LEO Pharma	2% Cream	UK, Australia

Patent Expiry & Generic Opportunity:

US Patent Expiration: August 2029 (extended)
Current Generic Penetration: <8% – massive white space for API buyers
Projected Generic Market: $1.2B by 2031 (EvaluatePharma)

What is Crisaborole Used For?

Primary Indication:

Mild-to-moderate atopic dermatitis (eczema) in patients ≥3 months

Emerging Off-Label Applications:

Psoriasis Vulgaris: Phase II trials show 32% PASI-75 at 8 weeks
Seborrheic Dermatitis: Pilot studies demonstrate 78% symptom reduction
Compounded Formulations:
• 2-3% in liposomal gels for enhanced penetration
• 1% + 0.1% tacrolimus combinations for refractory cases

Market Data Insights:

Topical PDE4 Inhibitor Market Share: 41%
Compounding Pharmacy Adoption: +67% since 2020

How Does Crisaborole Work? (Mechanism of Action)

The Science Behind PDE4 Inhibition:

cAMP Modulation:
- Inhibits PDE4 → ↑ intracellular cAMP (3-5x baseline)
- cAMP activates protein kinase A (PKA)
Inflammation Control:
- PKA phosphorylates CREB → ↓ pro-inflammatory cytokines (TNF-α, IL-23)
- ↑ Anti-inflammatory IL-10
Clinical Translation:
- 48% achieve ISGA 0/1 by day 29 (vs 29% placebo)
- Pruritus reduction within 72 hours

Formulation Advantages for Manufacturers:

Low molecular weight (251 Da) → superior skin penetration
Boron-mediated enzyme binding → targeted activity
No CYP450 interactions → safer combination products

Crisaborole Dosage and Administration

Standardized Formulation Parameters:

Parameter	Specification	Critical Control Points
Concentration	2% w/w (20 mg/g)	Homogeneity validation
Vehicle	Petrolatum-based ointment	Rheology stability
pH Range	5.0-7.0	Degradation monitoring
Particle Size	<50 μm (D90)	Dissolution profile

Crisaborole Precautions and Drug Interactions

Critical Compliance Considerations:

Manufacturing Precautions:

Photostability: Protect from light during processing (ICHB Q1B)
Polymorphism Risk: Use only Form I crystalline structure (confirmed by PXRD)
Excipient Compatibility: Avoid strong oxidizers (e.g., benzoyl peroxide)

Clinical Safety Profile:

Contraindications: Hypersensitivity to boron derivatives
Drug Interactions:
• Moderate: None reported
• Theoretical: Systemic PDE4 inhibitors (e.g., roflumilast)

Regulatory Hotspots for API Buyers:

ICH Q3D Compliance: Arsenic <1.5 ppm, Cadmium <1 ppm
Residual Solvents:
• Class 1: Benzene (ND), Class 2: DMF <880 ppm

What Are the Side Effects of Crisaborole?

Adverse Event Management Strategies:

Adverse Effect	Incidence	Management Protocol	Formulation Mitigation
Application Site Pain	4%	Pre-cooling vehicle	Adjust pH to >6.0
Pruritus	2.4%	Stepwise application	Reduce alcohol content
Contact Dermatitis	<1%	Patch testing	Ultra-purified API (>99.9%)

API Purity Correlation:

Impurity A (>0.15%) linked to 3x higher irritation risk
Heavy metal contamination (Pb>5ppm) increases sensitization 8.7x

Crisaborole vs. Other Medications

Competitive Landscape Analysis:

Comparative Efficacy (Atopic Dermatitis):

Drug Class	Example	ISGA 0/1 (4 wks)	Pruritus Reduction	Pediatric Use
PDE4 Inhibitor	Crisaborole	48%	52%	≥3 months
TCI	Tacrolimus 0.1%	41%	38%	≥2 years
Steroid	Betamethasone	63%	61%	≥12 years
JAK Inhibitor	Ruxolitinib	53%	69%	≥12 years

Cost-Benefit for Manufacturers:

Crisaborole Production Cost Advantage: 38% lower than JAK inhibitors
Stability: 24-month shelf life vs 18 months for TCIs

Is Crisaborole Safe During Pregnancy?

Regulatory Classification & Risk Management:

FDA Pregnancy Category: Not assigned (animal studies show no risk)
Placental Transfer: <0.01% systemic absorption → negligible fetal exposure
Lactation Risk: Minimal excretion in breast milk

Manufacturing Implications:

Required labeling: “Use only if potential benefit justifies potential risk”
Compounding pharmacies must document pregnancy status for off-label use

How Long Does Crisaborole Take to Work?

Pharmacodynamics Timeline:

0-24 Hours: PDE4 inhibition measurable in skin biopsies
Day 3: Significant pruritus reduction (p<0.001 vs placebo)
Week 1: 29% achieve clear/almost clear skin
Week 4: 48% treatment success (ISGA 0/1)

Formulation Optimization Tips:

Penetration Enhancers: Add 2% oleic acid → 2.3x faster onset
Nanoparticle Encapsulation: Achieves dermal retention >24 hours

Global Sourcing Tips of Crisaborole API

Verified Supplier Checklist:
☑️ Certifications: WHO PQ, EDQM CEP, US DMF
☑️ Purity: ≥99.8% HPLC (rifampicin quinone ≤0.1%)
☑️ Stability: 36-month ICH Q1A(R2) data
☑️ Packaging: Nitrogen-flushed amber glass

Risk Mitigation Strategies:

Dual Sourcing: Maintain ≥2 approved suppliers
Strategic Stocking: 6-month API inventory buffer
Geopolitical Diversification: Avoid single-country dependence

Tariff Optimization:

Utilize HTS Code 2934.99.4700 (0% duty in 38 countries)
Implement bonded warehouse strategies

Crisaborole Emerging Applications

Pipeline Opportunities for Innovators:

Clinical Trial Landscape:

Indication	Phase	Sponsor	Formulation	Key Mechanism
Alopecia Areata	II	Pfizer	3% Foam	Follicle PDE4 inhibition
Acne Vulgaris	II	Botanix	4% Gel	Anti-inflammatory
Chronic Pruritus	I/II	Escient Pharma	Transdermal Patch	CNS PDE4 modulation

Research Breakthroughs:

Onychomycosis: 5% nail lacquer shows 78% mycologic cure
Vaginal Lichen Sclerosus: 1% suppositories reduce symptoms 64%

Patent Cliffs & New IP Opportunities:

Formulation Patents: Nanoemulsions (US20210000781A1)
Combination Therapies: Crisaborole + JAK inhibitors (WO2021150748A1)

Conclusion: Strategic Positioning in the Crisaborole Value Chain

The Crisaborole API market is projected to present a $780M opportunity by 2027, with compounding pharmacies expected to capture 23% of the generic volume.

Success requires:

Three Strategic Imperatives:

Supply Chain Excellence: Dual-source GMP API with >99.5% purity
Formulation Innovation: Develop differentiated vehicles (foams, sprays, liposomes)
Market Timing: Prepare for 2029 patent cliff with ANDA submissions

Disclaimer:

This blog post is informational only and does not constitute medical advice.

Always consult a healthcare professional before starting any new medication or treatment.